H1 Revenue Doubles For Biota
Total revenue was $61.7m, up 84% from $33.5m on the comparable period last year. Revenue included $56.7m of Relenza royalties $1.4m of collaboration income from licensing agreements with
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
In the new study of treatment-experienced HIV-1-infected adults with no Prezista resistance-associated mutations (RAMs), 72% of patients in the Prezista/ritonavir (800/100 mg) once-daily arm achieved undetectable viral loads